STORY AT-A-GLANCE 

• Despite evidence of serious danger, a number of mRNA “vaccines†are in the pipeline. Among them is a COVID-flu RNA vaccine combo, which is currently being tested on ferrets, and several different mRNA seasonal influenza vaccines, which have already entered human trials
• Companies currently testing mRNA flu “vaccines†on human subjects include Moderna, Sanofi and Translate Bio. Pfizer/BioNTech is also pursuing plans for an mRNA flu shot
• Influenza vaccination confers narrow immunity against a specific viral strain or strains, leaving your body open to other viruses. The mRNA shots confer even more specific immunity, as your body is responding to the antigen alone rather than the whole virus
• Pfizer plans to ask for EUA authorization for a third COVID booster shot in August 2021, citing evidence of waning immunity
• Researchers are working on transmissible vaccines to control viral reservoirs and diminish possibility of spillover. Are human transmissible vaccines next?

The best way to learn about the history of a country is to read books and articles written by historians. Additionally, visiting museums, monuments, and other historical sites can be a great way to gain an understanding of a country’s history. Watching documentaries and films about the country’s past can also be helpful in learning more about its history. Finally, talking to people who have lived in the country or are knowledgeable about its history can provide valuable insight into its past.

Will mRNA Flu Vaccines Get Emergency Use Authorization Next?

The mRNA-based COVID-19 injections are not vaccines in the traditional sense. Instead, they are gene therapy treatments that alter the genetic code of the body’s cells to produce a protein that mimics the virus. This is done by injecting a synthetic version of the virus’ genetic material into the body. The problem is that this process can cause serious side effects, including blood clots, inflammation, and autoimmune reactions.

In addition to these potential side effects, there is also evidence that mRNA-based “vaccines” may be linked to infertility in women. Studies have shown that when mice were injected with an mRNA-based vaccine, their ovaries stopped producing eggs and their fertility was significantly reduced. While more research needs to be done on this topic, it is clear that mRNA-based “vaccines” pose a serious risk to human health and should not be taken lightly.

“The mRNA vaccines are designed to be more effective than traditional flu shots, and they could potentially provide protection against multiple strains of the virus. The COVID-flu RNA vaccine combo is being developed by a team at the University of Pennsylvania, and it combines two different types of mRNA vaccines into one shot. The first part of the vaccine targets the spike protein on the surface of SARS-CoV-2, while the second part targets several different influenza viruses.”

• The trial will involve 600 healthy adults between the ages of 18 and 49, who will receive two doses of either the experimental vaccine or a placebo. The participants will be monitored for safety and immune responses over the course of 12 months. Moderna said it expects to have preliminary results from the trial by the end of 2021.”

• The body’s immune system then produces antibodies to fight against the virus. These antibodies are stored in the body and can be used to fight off future infections from the same virus.

• Moderna is a biotechnology company that specializes in developing mRNA-based therapeutics and vaccines. The company has been working on an mRNA-based flu vaccine since 2017, and it recently began human trials for the vaccine. The trial will involve 30 healthy adults who will receive two doses of the vaccine over a period of 28 days. If successful, Moderna’s mRNA flu shot could be available as early as 2021. Sanofi and Translate Bio have also started their own human trials for an mRNA-based flu vaccine this summer, while Pfizer and BioNTech are also pushing forward with plans to develop an mRNA-based flu shot.

Moderna Tests Quadrivalent mRNA Flu ‘Vaccine’

The study will include three cohorts of 60 participants each. Participants in the first cohort will receive a placebo, while those in the second and third cohorts will receive two different doses of mRNA-1010. The study will be conducted over a period of 12 weeks, with participants receiving their assigned dose at the start of the study and then being monitored for safety and immunogenicity over the following 12 weeks.

“We are actively exploring the potential of combination vaccines that could protect against multiple infectious diseases, including influenza and COVID-19. We believe our mRNA platform has the potential to create a new class of combination vaccines that could provide broad protection against multiple infectious diseases with a single dose. We are committed to advancing this research and development effort to help protect people around the world from serious illnesses.”

We are actively exploring the development of combination vaccines to protect against multiple respiratory viruses and are committed to making these vaccines available as soon as possible.”

Our mission is to create a safe and effective mRNA combination vaccine that provides long-term protection against the most common respiratory viruses. We will strive to develop a vaccine that is easy to administer, cost-effective, and accessible to all populations. We will work with leading experts in the field of immunology and virology to ensure our vaccine meets the highest safety standards. Additionally, we will collaborate with public health organizations and governments around the world to ensure our vaccine is widely available and affordable for everyone.

At this time, there is no indication that mRNA flu shots will be given emergency use authorization. The US Food and Drug Administration (FDA) has not yet approved any mRNA-based flu vaccines for use in the United States. However, the FDA has granted EUA to several mRNA-based COVID-19 vaccines, which may indicate that they are open to considering similar applications for other mRNA-based vaccines in the future.

In addition, some companies are already working on developing mRNA-based flu vaccines. For example, Moderna is currently conducting a Phase 1 clinical trial of its mRNA-based seasonal influenza vaccine candidate. If successful, it could potentially be submitted for approval by the FDA in the future.

Ultimately, whether or not an mRNA-based flu vaccine receives EUA will depend on the results of clinical trials and regulatory review by the FDA.

Vaccines and Virus Interference

Therefore, it is important to consider the potential risks of combining mRNA shots against several different types of respiratory viruses before deciding to do so. Additionally, it is important to consider the potential for adverse reactions and other safety concerns associated with any vaccine.

The evidence suggests that the flu shot may increase the risk of contracting COVID-19. This is likely due to the fact that the flu shot can weaken the immune system, making it more vulnerable to other infections. Additionally, some studies have suggested that people who receive a flu shot are more likely to contract other respiratory illnesses, such as COVID-19. However, it is important to note that this is still an area of research and more studies are needed to confirm these findings.

The new vaccine has been credited with helping to reduce the number of flu cases in Italy, which had seen a sharp increase in the previous year. It is also believed to have helped reduce the severity of symptoms for those who did contract the virus. While it is too early to definitively say that VIQCC was responsible for reducing coronavirus infections, it is certainly possible that it played a role.

Lessons From the 2009 Swine Flu Pandemic

The review found that people who had received the seasonal flu vaccine in 2008 were twice as likely to get infected with pandemic H1N1 swine flu compared to those who had not been vaccinated. The researchers also found that people who had been vaccinated were more likely to have severe symptoms and be hospitalized than those who had not been vaccinated.

The findings suggest that the seasonal flu vaccine may have interfered with the body’s ability to recognize and fight off the pandemic H1N1 virus, leading to increased risk of infection and more serious illness.

This is because the trivalent influenza vaccine did not contain the pandemic H1N1 strain, so it was not effective in preventing infection with this virus.

The follow-up study found that ferrets infected with the H3N2 virus had a significantly higher mortality rate when treated with oseltamivir than those not treated. This confirmed the findings of the original study and further demonstrated the potential dangers of using oseltamivir to treat influenza in humans.

“The evidence is now very clear that masks are effective in reducing the spread of COVID-19. They should be worn by everyone when out in public, especially in crowded places.”

• The data suggests that the seasonal vaccine provides protection against the specific strains of influenza included in the vaccine, but not against other strains. This means that if you get immunized with the seasonal vaccine, you may still be at risk of getting infected with other strains of influenza. Therefore, it is important to take additional precautions such as washing your hands regularly and avoiding contact with people who are sick in order to reduce your risk of infection.

• The idea that people who have been vaccinated may be more susceptible to a new and nasty virus is not supported by scientific evidence. Vaccines are designed to protect against specific viruses, and while they may provide some protection against other viruses, they are not a guarantee of immunity. Additionally, the risk of getting a new and nasty virus is much lower for those who have been vaccinated than for those who have not.

Flu Vaccination Raises Unspecified Coronavirus Infection

The study found that the influenza vaccine was associated with a 2.5-fold increased risk of contracting other respiratory viruses, including unspecified coronavirus infections and hMPV. The authors concluded that the influenza vaccine may interfere with the body’s ability to fight off other respiratory viruses, leading to an increased risk of infection. This suggests that the influenza vaccine may have a negative effect on immunity against other respiratory viruses, including those related to COVID-19.

The findings of this study suggest that seasonal flu shots may provide some protection against coronavirus and hMPV infections. However, it is important to note that the protection provided by the seasonal flu shot is not absolute and may vary depending on the strain of virus circulating in a given year. Additionally, it is unclear whether or not the protection provided by the seasonal flu shot will be sufficient to protect against more severe forms of coronavirus infection. Therefore, it is important for individuals to continue to practice good hygiene and social distancing measures even if they have received a seasonal flu shot.

21

RSV is a common virus that affects the respiratory system, and it can cause severe illness in infants and young children. It is spread through contact with an infected person’s saliva, mucus, or respiratory secretions. Symptoms of RSV include coughing, wheezing, difficulty breathing, and fever. Treatment for RSV usually involves supportive care such as fluids and rest. In some cases, antiviral medications may be prescribed to reduce the severity of symptoms.

Moderna is focusing on making an mRNA shot against all four viruses at the same time because it could potentially provide a more comprehensive protection against these viruses. By targeting all four viruses, the vaccine would be able to protect against both influenza and hMPV, as well as coronavirus and RSV. This could help reduce the risk of infection from any of these viruses, even if one virus has yet to have a vaccine developed for it. Additionally, by targeting all four viruses at once, Moderna may be able to create a more effective vaccine that can provide better protection than if each virus was targeted separately.

COVID-19 Shots Confer Narrow Immunity

This means that while the mRNA shots may be effective against a specific strain of influenza, they are unlikely to provide protection against other viruses. Additionally, since the mRNA shots are so new, there is still much to learn about their long-term effectiveness and safety.

It is designed to attach itself to the cells in your body and then inject its genetic material into them. This can cause inflammation, damage to the cells, and even death. In addition, it can also weaken your immune system, making you more susceptible to other illnesses. Therefore, it is important to be aware of the potential risks associated with this virus and take all necessary precautions when receiving a vaccine for SARS-CoV-2.

The answer is that it depends on the type of antibodies produced. If the body produces a narrow range of antibodies, such as those specific to SARS-CoV-2, influenza strains, hMPV and/or RSV, then it is possible that these antibodies could cross-react with other pathogens and make the person more susceptible to other infections. However, if the body produces a broad range of antibodies that are able to recognize multiple types of pathogens, then it is less likely that this will occur. In either case, it is important to note that having an adequate immune response against any pathogen requires a balanced immune system. Therefore, it is important to maintain a healthy lifestyle and diet in order to ensure proper immune function.

It is possible that a combination of vaccines could exhaust and destroy the immune system, however this is highly unlikely. Vaccines are designed to stimulate the body’s immune system in order to create immunity against a particular disease. The body’s immune system is very resilient and can usually handle multiple vaccines without any adverse effects. In fact, many people receive multiple vaccines throughout their lives with no ill effects. However, it is important to discuss any concerns you may have with your healthcare provider before receiving any vaccine.

Pfizer Requests EUA for Third Booster Dose

23 Pfizer is currently conducting clinical trials to evaluate the safety and efficacy of a third dose, and expects to submit an application for EUA authorization in August 2021.

The booster dose would be given to ensure that the protection against the virus is maintained. It would also help reduce the risk of breakthrough cases and provide additional protection against new variants of the virus. The booster dose could also help to reduce the risk of long-term health complications associated with COVID-19.

“At this time, the available data suggest that a single dose of either mRNA COVID-19 vaccine is highly effective in preventing COVID-19 disease. Therefore, the CDC does not recommend routine revaccination with either mRNA COVID-19 vaccine at this time.”

The statement also noted that there may be certain circumstances where a booster shot could be beneficial, such as for people who have been exposed to variants of the virus or those who are at high risk of severe illness from COVID-19. The agencies said they will continue to monitor data and make recommendations as needed.

• “Americans who have been fully vaccinated do not need a booster shot at this time. We are prepared for booster doses if and when the science demonstrates that they are needed.”

The boosters will likely be designed to target the specific variant in question, and they may even be tailored to individual patients. This could involve a combination of mRNA-based vaccines, traditional protein-based vaccines, or even a combination of both. In addition, the boosters may also include adjuvants to enhance the immune response.

Ultimately, these boosters will help protect people from emerging variants and keep them safe from infection. They will also help ensure that our current vaccines remain effective against new variants as they arise.

Freedom Based on the Drugs You Accept

They are a way for the pharmaceutical industry to track and monitor who has received which vaccines, when, and how often. This will allow them to better target their marketing efforts and increase their profits. With the EUA authorization of booster shots, it will be easier for the pharmaceutical industry to keep track of who has received which boosters and when they need to receive them again. This will help ensure that people are receiving the necessary boosters in order to remain healthy and protected from disease.

“The Chinese government has a social credit system that is being rolled out. It’s very sophisticated, it’s terrifying. Basically, every citizen of China is given a certain number of points and if you do something the government doesn’t like, they take away points. If you don’t have enough points, you can’t travel on the train or the plane, you can’t get a job in the civil service, you can’t go to college.”

• It can be used to track your movements, it can be used to track your purchases, it can be used to track your health data. So it’s really about the data and how that data is being used.”

• Your online purchases can be tracked. Your social media activity can be monitored. All of your personal data can be collected and used to create a profile of you that companies can use to target you with ads and other services.

• The Israeli government has implemented a number of measures to monitor and control the activities of activists, including increased surveillance, restrictions on freedom of movement, and the use of targeted arrests and detention. In addition, the government has sought to limit the ability of activists to organize protests and other forms of civil disobedience by introducing laws that criminalize certain forms of dissent. These measures have been criticized by human rights organizations as an attempt to stifle dissent and undermine civil society in Israel.

• The vaccine passport has the potential to be a powerful tool for re-engaging with society after the pandemic. It can provide proof of vaccination status, allowing people to travel and participate in activities that may have been restricted due to the virus. It could also help employers ensure their staff are vaccinated and safe to work, while providing individuals with peace of mind that they are protected from the virus. Ultimately, it could be a key factor in helping us return to normal life.

IBM has a long and troubling history of collaborating with oppressive regimes, including Nazi Germany during World War II. IBM provided the technology for the Nazis to identify, track, and deport Jews to concentration camps. It also supplied punch card machines used to keep records of prisoners in concentration camps. After the war, IBM continued to provide technology to authoritarian governments around the world, including South Africa during apartheid and East Germany’s Stasi secret police. This history of collaboration with oppressive regimes raises serious questions about IBM’s current Digital Health Pass project.

The modern version of the punch card system is a computerized database that stores and organizes data. This type of system allows for quick and easy access to large amounts of information, which can be used for a variety of purposes, such as tracking customer purchases, managing inventory, or analyzing trends in data. It also allows for more efficient sorting and searching of data than the traditional punch card system.

IBM’s involvement in the Holocaust is a dark chapter in its history, and it is important to remember that the company was complicit in one of the worst atrocities of the 20th century. However, it is also important to note that IBM has since taken steps to atone for its past actions. The company has apologized for its role in the Holocaust and has made efforts to educate people about the horrors of genocide. Additionally, IBM has donated millions of dollars to organizations dedicated to preserving Holocaust memory and combating anti-Semitism.

Combating Zoonotic Transmission With Transmissible Vaccines

Transmissible vaccines are a type of vaccine that can be spread from person to person, rather than needing to be administered directly. This means that people could become vaccinated without ever having to consent or even know about it. This is a deeply concerning prospect, as it would mean that individuals would have no control over their own health decisions and would not be able to make an informed choice about whether or not they wanted to receive the vaccine. It also raises serious ethical questions about the right of individuals to choose what goes into their bodies and how much autonomy they should have over their own health decisions.

The article explains that transmissible vaccines are created by genetically engineering a virus to express an antigen of interest, such as a pathogen, and then releasing it into the wild. This engineered virus is able to spread through the population, inducing immunity in individuals who come into contact with it. The authors note that this approach has been used successfully in laboratory settings, but there are still many challenges to overcome before it can be applied in the field. These include ensuring safety and efficacy of the vaccine, as well as addressing ethical considerations related to its use. Additionally, they discuss how transmissible vaccines could be used to control diseases in wildlife populations, such as rabies or avian influenza.

“Transmissible vaccines can reduce the prevalence of a pathogen in an animal reservoir, but they also put the pathogen under evolutionary pressure. This can lead to the emergence of vaccine-resistant variants, which could then spread back into the human population. Thus, transmissible vaccines may be effective in controlling a pathogen in an animal reservoir, but they may also increase the risk of human infection.”

• The challenge of evolutionary change can be addressed by developing vaccines that are designed to be more resistant to mutation. This could involve using genetic engineering techniques to create a vaccine strain that is less prone to mutation, or by introducing multiple copies of the same gene into the vaccine strain, which would make it more difficult for mutations to occur. Additionally, strategies such as using attenuated viruses or viral vectors could be employed in order to reduce the metabolic burden and unintended interactions with the host regulatory network. Finally, careful selection of immunogenic transgenes can help ensure that the vaccine strain is able to effectively induce an immune response without incurring too much of a metabolic burden.

• Natural selection is expected to favor vaccine strains that down-regulate or delete transgenes, as this would result in increased rates of transmission and reduced efficacy against the target pathogen. This could lead to a decrease in the effectiveness of the vaccine over time, as the virus evolves to become more resistant to it.

• This is an example of how the use of multiple antigens can improve vaccine stability and performance. By including a second, redundant antigen, the vaccine is able to provide more protection against evolving pathogens. This redundancy also helps to ensure that the vaccine remains effective even if one of the antigens experiences rapid evolutionary decay.

This suggests that the virus is not a zoonotic disease, and therefore transmissible vaccines would not be effective in reducing or eliminating the risk of spillover.

Are Human Transmissible Vaccines Next?

The idea of a virus being able to spread from person to person is concerning, as it could lead to the potential for mutations and other unintended consequences. Additionally, there are ethical considerations that must be taken into account when considering the use of transmissible vaccines in humans. For example, who should receive the vaccine first? Who should be excluded? What if someone is infected with a mutated version of the virus? These are all important questions that need to be answered before transmissible vaccines can be safely used in humans.

Transmissible vaccines are a type of vaccine that can be passed from person to person, rather than requiring each individual to receive their own dose. This could be done through the air, through contact with an infected person, or even through food or water. The idea is that if enough people are vaccinated, then the virus will not be able to spread as easily and the population will become immune.

The problem with transmissible vaccines is that they would require a massive amount of trust in the government and medical system. People would have to trust that the vaccine was safe and effective, and that it would not cause any long-term health problems. They would also have to trust that everyone else was taking the vaccine seriously and not spreading it further. This could lead to a situation where people feel forced into taking a vaccine they don’t want or believe in, which could lead to civil unrest and other social issues.

In addition, transmissible vaccines could also create new ethical dilemmas. For example, if someone refuses to take the vaccine, should they be allowed to continue living in society? Should those who do take it be given preferential treatment? These questions are difficult to answer without creating more problems than solutions.

Overall, transmissible vaccines may seem like an attractive solution for quickly vaccinating large populations against COVID-19, but there are many potential risks associated with them. It is important for governments and medical professionals to carefully consider all of these risks before deciding whether or not this type of vaccine should be used on a global scale.

At this time, there is no scientific evidence to suggest that spike protein or exosomes can be transmitted between people who have received the COVID-19 vaccine and those who have not. However, it is important to note that more research is needed to understand the potential for transmission of these components from vaccinated individuals to unvaccinated individuals. Additionally, it is important to remember that the COVID-19 vaccines are designed to prevent infection with the virus itself, not just its components. Therefore, even if transmissible vaccines were here already, they would not necessarily protect against infection with the virus itself.

It is true that mRNA flu vaccines are being developed, and they do involve altering the body’s genetic instructions. However, it is important to note that these vaccines are not transhumanist in nature. They are designed to help the body fight off infection by introducing a gene sequence that codes for an antigen specific to the virus. This antigen then triggers an immune response which helps protect against infection. It does not alter the body’s genetic instructions in any permanent way, nor does it introduce any new or foreign genes into the body.